Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95.3Revenue (TTM) $M36.0Net Margin (%)-68.6Altman Z-Score-6.7
Enterprise Value $M171EPS (TTM) $-0.4Operating Margin %-54.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.9Pre-tax Margin (%)-68.1Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio4.5Cash flow > EarningsY
Price/Sales2.45-y EBITDA Growth Rate %-6.9Current Ratio4.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-37.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-112.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M69.1ROIC % (ttm)-68.2Gross Margin Increase y-yN

Gurus Latest Trades with ALIM

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ALIM is held by these investors:



ALIM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Myers C. DanielCEO 2017-03-10Sell21,172$1.39-0.72view
Roberts Calvin W.Director 2016-12-12Sell50,000$1.1124.32view
EISWIRTH RICHARD S JRPresident and CFO 2016-09-15Sell51,471$1.51-8.61view
BAVP, L.P.10% Owner 2016-04-21Sell478,673$2.59-46.72view
EISWIRTH RICHARD S JRCOO and CFO 2015-12-16Sell46,669$2.31-40.26view
Flynn James E 2015-12-08Buy272,249$3.01-54.15view
Flynn James E 2015-12-03Buy243,252$3-54view
Flynn James E 2015-11-06Buy73,250$2.98-53.69view
Flynn James E 2015-10-30Buy16,542$3-54view
Flynn James E 2015-10-28Buy59,342$3-54view

Press Releases about ALIM :

Quarterly/Annual Reports about ALIM:

    News about ALIM:

    Articles On GuruFocus.com
    Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference Sep 19 2017 
    Alimera Sciences Announces ILUVIEN® now available in Ireland Sep 12 2017 
    Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investme Sep 11 2017 
    Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congr Sep 05 2017 
    Alimera Sciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Aug 31 2017 
    Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in France Aug 29 2017 
    Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting Aug 09 2017 
    Alimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Op Aug 07 2017 
    Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Tre Jul 25 2017 
    Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017 Jul 24 2017 

    More From Other Websites
    Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference Sep 19 2017
    Alimera Sciences Announces ILUVIEN® now available in Ireland Sep 12 2017
    Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global... Sep 11 2017
    ETFs with exposure to Alimera Sciences, Inc. : September 9, 2017 Sep 08 2017
    Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017 Sep 07 2017
    Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina... Sep 05 2017
    Alimera Sciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Aug 31 2017
    Edited Transcript of ALIM earnings conference call or presentation 3-Aug-17 1:00pm GMT Aug 13 2017
    Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting Aug 09 2017
    Alimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During... Aug 07 2017
    Alimera Sciences reports 2Q loss Aug 04 2017
    Investor Network: ALIMERA SCIENCES INC to Host Earnings Call Aug 03 2017
    Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN®... Jul 25 2017
    Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017 Jul 24 2017
    Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in... Jul 19 2017
    ETFs with exposure to Alimera Sciences, Inc. : July 13, 2017 Jul 13 2017
    Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN® Jul 12 2017
    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta... Jul 12 2017
    5 Top Multibagger Biotech Stocks to Buy in the 2nd Half Jul 11 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}